CFO Moss and CEO Tesi of INmune Bio purchased shares, while the firm reported negative earnings and increased institutional interest, with Scotiabank setting a $22 target price.

CFO David J. Moss and CEO Raymond J. Tesi of INmune Bio (NASDAQ: INMB) recently bought shares, with Moss acquiring $49,062 worth and Tesi $98,124, raising their total ownership to 1.27 million and 1.55 million shares, respectively. The clinical-stage immunology firm, focusing on treatments for cancers and chronic inflammation, reported negative earnings and has seen increasing institutional interest. Scotiabank set a target price of $22 for the stock.

September 19, 2024
4 Articles